An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).

Phase 1

AstraZeneca